Extended-Spectrum β-Lactamase- and Carbapenemase-Producing Enterobacteriaceae Isolated from Egyptian Patients with Suspected Blood Stream Infection
Overview
Authors
Affiliations
Objectives: The aim of the study was to investigate the prevalence of extended-spectrum β-lactamase and carbapenemase production among Enterobacteriaceae isolated from Egyptian patients with suspected blood stream infection.
Methods: Ninety-four Enterobacteriaceae blood culture isolates from Egyptian patients with suspected blood stream infection were collected, one isolate per patient. Identification of bacterial isolates was performed with MALDI-TOF (MS-based Vitek MS system, bioMerieux). Screening for ESBLs and carbapenemases production was done with the Vitek 2 system (bioMérieux). ESBL production was confirmed using the combined disk diffusion method for cefotaxime, ceftazidime, and cefepime, all with and without clavulanic acid (Rosco). Real-time PCR and sequencing were used to characterize the resistance genes. The phylogenetic groups of E. coli were identified by a PCR-based method.
Results: Of the 94 Enterobacteriaceae isolates 46 (48.93%) showed an ESBL phenotype. One Enterobacter spp isolate was ESBL-producer and meropenem-resistant. The genetic analysis showed that CTX-M was present in 89.13% (41/46) of the ESBL-producing Enterobacteriaceae, whereas TEM and SHV were detected in 56.52% (26/46) and 21.74% (10/46) respectively (47.83%) of the ESBL-producing isolates were multidrug resistant (MDR). Eleven out of 30 ESBL-producing E-coli isolates were assigned to phylogroup B2, followed by groups B1 (8 isolates), A (6 isolates) and D (5 isolates).
Conclusions: The high ESBL-E rates (48.93%) found in this study together with the identification of one carbapenem-resistant Enterobacter spp isolate is worrisome. Our results indicate that systems for monitoring and detection of ESBL-producing bacteria in Egyptian hospitals have to be established. Also strict hospital infection control policies with the restriction of the consumption of extended-spectrum cephalosporins are necessary.
Qu S, Zheng S, Muhammad S, Huang L, Guo B J Nanobiotechnology. 2025; 23(1):184.
PMID: 40050881 PMC: 11887204. DOI: 10.1186/s12951-025-03230-3.
Birhanu A, Gebre G, Getaneh E, Yohannes H, Baye N, Mersha G Sci Rep. 2025; 15(1):5769.
PMID: 39962179 PMC: 11833138. DOI: 10.1038/s41598-025-86648-x.
Haji S, Ganjo A, Abdulaziz S, Abdullah Z, Smail S Cureus. 2025; 17(1):e77269.
PMID: 39931609 PMC: 11808409. DOI: 10.7759/cureus.77269.
Azzam A, Khaled H, Samer D, Nageeb W Antimicrob Resist Infect Control. 2024; 13(1):145.
PMID: 39639352 PMC: 11622690. DOI: 10.1186/s13756-024-01497-z.
Samir A, Abdel-Moein K, Zaher H Acta Vet Scand. 2024; 66(1):54.
PMID: 39363309 PMC: 11448284. DOI: 10.1186/s13028-024-00774-6.